Does Blue Cross Blue Shield of Michigan Cover Trulicity?

How BCBSM Classifies Trulicity on Its Formulary

Blue Cross Blue Shield of Michigan maintains a multi-tier formulary that categorizes drugs by cost and clinical preference. Trulicity (dulaglutide) appears on the BCBSM formulary for both commercial PPO/HMO plans and Blue Care Network (BCN) HMO plans, though its exact tier placement varies by plan year and benefit design.

Preferred vs. Non-Preferred Brand Placement

On most BCBSM commercial plans, Trulicity is listed as a preferred brand (Tier 2) or non-preferred brand (Tier 3) injectable. Preferred brand placement carries lower copays, typically $30 to $60 per 30-day supply. Non-preferred placement pushes that copay to $75 to $150. Your plan's Summary of Benefits and Coverage (SBC) document will confirm the exact tier.

Blue Care Network (BCN) Plans

BCN HMO plans managed by BCBSM use a separate formulary. Trulicity is generally covered under BCN plans with similar prior authorization requirements, but step-therapy protocols may differ. BCN members should check the BCN formulary search tool or call member services at the number on the back of their insurance card.

How to Verify Your Specific Coverage

The fastest way to confirm coverage is to log in to your BCBSM member portal and use the prescription drug lookup tool. Enter "dulaglutide" or "Trulicity" and select your plan. The tool will display your tier, estimated copay, and any coverage restrictions like prior authorization or quantity limits.

Prior Authorization Requirements for Trulicity

BCBSM requires prior authorization (PA) for Trulicity on the majority of its plans. This means your prescribing clinician must submit documentation to BCBSM proving that the medication is medically necessary before the pharmacy can dispense it.

What BCBSM Typically Requires

The PA criteria for GLP-1 receptor agonists at BCBSM generally follow this pattern: a confirmed diagnosis of type 2 diabetes mellitus, a documented trial of metformin (or a valid clinical reason for not using metformin, such as renal impairment with an eGFR <30 mL/min/1.73 m² or gastrointestinal intolerance), and a recent HbA1c value showing inadequate glycemic control (usually HbA1c ≥ 7.0%). The American Diabetes Association (ADA) Standards of Care 2024 recommend GLP-1 receptor agonists as second-line therapy after metformin, particularly in patients with established atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk [1].

Timeline for PA Decisions

BCBSM typically processes standard prior authorization requests within 72 hours. Urgent requests, where a delay could seriously harm the patient, are reviewed within 24 hours. If the PA is denied, your provider can file a peer-to-peer review or a formal appeal.

Step Therapy and Its Implications

Many BCBSM plans enforce step therapy for GLP-1 receptor agonists. In practice, this means a patient must have tried and failed (or be contraindicated for) metformin before Trulicity can be approved. Some plans also require a trial of a sulfonylurea or SGLT2 inhibitor. The ADA consensus report notes that GLP-1 RAs should be considered early in the treatment algorithm for patients with ASCVD, heart failure, or chronic kidney disease, regardless of HbA1c level [2].

Trulicity Costs Under BCBSM Plans

Out-of-pocket cost depends on your plan tier, deductible status, and whether you have met your annual out-of-pocket maximum. Without insurance, Trulicity's list price is approximately $1,067 per month for the 1.5 mg dose (four weekly pens per carton).

Estimating Your Copay

For a BCBSM member with Trulicity on Tier 2 (preferred brand), a typical copay runs $30 to $60 after any applicable deductible. Tier 3 (non-preferred brand) copays range from $75 to $150. High-deductible health plans (HDHPs) paired with a health savings account (HSA) may require the member to pay the full negotiated rate until the deductible is met, which could exceed $300 per fill early in the plan year.

The Lilly Trulicity Savings Card

Eli Lilly offers a manufacturer savings card that can reduce monthly copays to as low as $25 for commercially insured patients. The card covers up to $150 per prescription fill and can be used for up to 24 months. Patients with government-funded insurance (Medicare, Medicaid, Tricare) are not eligible for this program, per federal anti-kickback regulations.

Medicare Advantage Through BCBSM

BCBSM offers several Medicare Advantage Prescription Drug (MAPD) plans across Michigan. Trulicity is covered under Medicare Part D, and BCBSM's MAPD formularies typically list it on Tier 3 or a specialty tier. Medicare beneficiaries should expect to pay 25% to 33% coinsurance after the deductible phase, though the Inflation Reduction Act cap of $2,000 in annual out-of-pocket Part D costs (effective 2025) limits total yearly spending [3].

Clinical Evidence Supporting Trulicity

Understanding why insurers cover Trulicity helps clarify its medical necessity. Dulaglutide is a once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction.

Glycemic Control: AWARD Trial Program

The AWARD clinical trial program evaluated dulaglutide across multiple comparator studies. In AWARD-1 (N=978), dulaglutide 1.5 mg reduced HbA1c by 1.61% at 52 weeks compared to 0.46% with placebo [4]. The 0.75 mg dose achieved a 1.30% reduction. These results established dulaglutide as one of the more effective GLP-1 RAs for glucose lowering.

Cardiovascular Outcomes: REWIND Trial

The REWIND trial (N=9,901) followed patients with type 2 diabetes for a median of 5.4 years. Dulaglutide 1.5 mg reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 12% compared to placebo (HR 0.88, 95% CI 0.79 to 0.99) [5]. REWIND was notable because 69% of participants did not have established cardiovascular disease at baseline, broadening the evidence base for dulaglutide's cardioprotective effect to a primary prevention population.

Weight Effects

Across the AWARD program, dulaglutide 1.5 mg produced weight loss of approximately 1.5 to 3.0 kg relative to baseline, depending on the comparator. This is modest compared to semaglutide 2.4 mg, which achieved 14.9% body weight loss in the STEP-1 trial (N=1,961) [6]. Trulicity is FDA-approved for type 2 diabetes management, not for weight loss as a primary indication.

How Trulicity Compares to Other Covered GLP-1 RAs at BCBSM

BCBSM covers several GLP-1 receptor agonists, and formulary position can shift from year to year. Knowing how Trulicity stacks up against alternatives helps you and your prescriber choose the best option from both a clinical and cost standpoint.

Ozempic (Semaglutide)

Ozempic typically sits on the same tier as Trulicity on BCBSM plans. The SUSTAIN-7 trial (N=1,201) directly compared semaglutide 1.0 mg to dulaglutide 1.5 mg and found semaglutide produced greater HbA1c reduction (1.8% vs. 1.4%) and more weight loss (6.5 kg vs. 3.0 kg) at 40 weeks [7]. Some BCBSM plans prefer one over the other, so tier placement should drive the cost conversation.

Mounjaro (Tirzepatide)

Tirzepatide, a dual GIP/GLP-1 receptor agonist, may be covered on BCBSM plans for type 2 diabetes. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg achieved a 2.58% HbA1c reduction and 12.4 kg weight loss at 40 weeks, surpassing semaglutide 1.0 mg on both endpoints [8]. Mounjaro is often placed on a higher tier (Tier 3 or specialty) and may face stricter PA criteria.

Switching Between Agents

If your provider wants to switch you from Trulicity to another GLP-1 RA (or vice versa), BCBSM may require a new prior authorization. The ADA recommends that clinicians consider cardiovascular benefit, weight effect, route of administration, and cost when selecting among GLP-1 RAs [1]. Document the clinical rationale for the switch in the PA request to speed approval.

How to Appeal a BCBSM Denial for Trulicity

A denied prior authorization is not the final answer. BCBSM offers a structured appeals process that gives patients and providers multiple opportunities to overturn a coverage decision.

Internal Appeal Steps

First, your prescriber can request a peer-to-peer review with a BCBSM medical director. This is an informal conversation where your doctor explains why Trulicity is medically necessary. If the peer-to-peer fails, you can file a formal Level 1 internal appeal within 180 days of the denial. BCBSM must respond within 30 calendar days for standard appeals and 72 hours for expedited appeals.

External Review

If the internal appeal is denied, Michigan law entitles you to an external review by an independent review organization (IRO). The Michigan Department of Insurance and Financial Services (DIFS) oversees this process. The IRO's decision is binding on BCBSM. Patients rarely reach this stage, as the majority of GLP-1 RA denials are overturned at the peer-to-peer or Level 1 appeal stage when adequate documentation is provided.

Tips for a Successful Appeal

Include a letter of medical necessity from your prescriber that references the ADA Standards of Care and the REWIND cardiovascular outcomes data. Attach lab results showing an HbA1c ≥ 7.0% despite metformin therapy, and document any contraindications to preferred alternatives. If your denial was based on step therapy, show evidence that the required step was tried (with dates, doses, and reasons for discontinuation).

Trulicity Dosing and Administration Basics

Trulicity is administered as a once-weekly subcutaneous injection using a prefilled, single-dose pen. The standard starting dose is 0.75 mg weekly, which can be titrated to 1.5 mg, 3.0 mg, or 4.5 mg based on glycemic response and tolerability per the FDA prescribing information [9].

Injection Sites and Timing

Patients inject Trulicity into the abdomen, thigh, or upper arm. The pen has a hidden needle and requires no reconstitution. Injections should be given on the same day each week, though the day can be changed as long as at least three days (72 hours) have passed since the last dose.

Common Side Effects

The most frequent adverse effects are gastrointestinal: nausea (12.4% in AWARD trials), diarrhea (8.9%), and vomiting (6.0%) [4]. These symptoms tend to diminish after the first four to eight weeks of treatment. Slow dose titration reduces GI side-effect severity. Pancreatitis is a rare but serious risk; patients should report persistent, severe abdominal pain immediately.

Storage Requirements

Unopened Trulicity pens should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). A pen can be kept at room temperature (up to 30°C / 86°F) for up to 14 days if needed for travel or convenience. Do not freeze the pen, and discard it if it has been frozen.

Michigan-Specific Resources for Prescription Assistance

Michigan residents who face high out-of-pocket costs for Trulicity have several resources beyond the Lilly savings card.

Michigan Prescription Drug Programs

The Michigan Department of Health and Human Services administers the Healthy Michigan Plan, which provides Medicaid coverage to adults with household incomes up to 138% of the federal poverty level. Trulicity is covered under Michigan Medicaid, though prior authorization applies. The Michigan Medicare/Medicaid Assistance Program (MMAP) offers free counseling to Medicare beneficiaries navigating Part D coverage.

Patient Assistance Programs

Eli Lilly's Lilly Cares Foundation provides Trulicity at no cost to qualifying uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level. Applications require a prescriber signature and proof of income. Processing takes approximately two to four weeks.

Trulicity is dispensed through retail and specialty pharmacies in Michigan. BCBSM members should verify whether their plan requires use of a preferred pharmacy network, as using an out-of-network pharmacy can increase copays by 50% or more. For the 4.5 mg dose, some BCBSM plans route fills through specialty pharmacy channels with separate copay structures [9].